Subtitle
Hypofractionated proton beam therapy for centrally located lung cancer.
Subtitle
Hypofractionated proton beam therapy for centrally located lung cancer.
Proto therapy Time
May 2019
Executive summary
This study from Japan reported outcomes of 39 patients who received hypofractionated PBT for centrally located cT1-2N0M0. Twenty-four patients (62%) were treated with 80 Gy (RBE) in 20 fractions, whereas eight (21%) were treated with 66 Gy (RBE) in 10 fractions. The 2-year progression-free survival (PFS) and overall survival (OS) rates were 86 and 100% for T1 disease and 56 and 94% for T2 disease.
Dyspnoea of grade 3 was noted in one patient (3%), and pneumonitis of grade 2 was noted in four patients (10%). The authors concluded that hypofractionated PBT may be a very safe and effective treatment option for centrally located early lung cancer.
Key content topics
Top cancer treatments
Related contents
Webinar
18 October 2024
Empowering Cancer Care with Proton Therapy
Rakesh
Jalali
Srinivas
Chilukuri
Daniela
Alterio
Proton Therapy Publication
July 2024
Quantifying dose uncertainties resulting from cardiorespiratory motion in intensity-modulated proton therapy for cardiac stereotactic body radiotherapy.
Proton Therapy Publication
July 2024
Initial experience and patient tolerance of proton stereotactic body radiotherapy.
Proton Therapy Publication
March 2024
A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry.
Webinar
March 29, 2023
Hypofractionation in Proton Therapy: radiobiological bases and clinical applications
Roberto
Orecchia
Barbara
Jereczek
Daniela
Alterio
Dante
Amelio
Jiri
Kubes
Proton Therapy Publication
March 2023
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Proton Therapy Publication
November 2022
Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis.
Proton Therapy Publication
May 2022
The Role of Hypofractionation in Proton Therapy.
Proton Therapy Publication
April 2022
Outcome after Radiotherapy for Vestibular Schwannomas – Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy.